Neurofibromatosis Type 2
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: An autosomal dominant disorder caused by mutations in the NF2 tumor suppressor gene. It is characterized by the development of peripheral and central nervous system tumors including acoustic schwannomas, neurofibromas, gliomas, and meningiomas. 
There are 3 clinical trials for neurofibromatosis type 2, of which 3 are open and 0 are completed or closed. Of the trials that contain neurofibromatosis type 2 as an inclusion criterion, 3 are phase 2 (3 open).
NF2 is the most frequent gene inclusion criterion for neurofibromatosis type 2 clinical trials .
Brigatinib, crizotinib, and selumetinib are the most common interventions in neurofibromatosis type 2 clinical trials.
Significant Genes in Neurofibromatosis Type 2
NF2 is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 2, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and neurofibromatosis type 2 as inclusion criteria, 1 is phase 2 (1 open) .
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.